Progression-free survival (PFS) is no longer a useful surrogate endpoint for overall survival (OS) in trials of newer ovarian cancer therapies, Australian researchers have shown. While correlation between PFS and OS for treatment effect was relatively good in the pre-platinum/paclitaxel era (R2 = 0.66), PFS had a poor correlation with OS in more recent trials of ...
PFS is a poor primary endpoint for new cancer therapies: study
By Michael Woodhead
15 Aug 2018